The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Direct Oral Anticoagulants (DOACs) Device Market By The End Of 2030?
The direct oral anticoagulants (doacs) device market has experienced significant growth in recent years. It will grow from $32.8 billion in 2025 to $35.69 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. Factors contributing to its historical expansion include the limited availability of doac monitoring devices, a reliance on hospital-based coagulation tests, the growing prevalence of atrial fibrillation and thrombotic disorders, the adoption of oral anticoagulant therapies, and an increasing demand for patient safety and effective anticoagulation monitoring.
The direct oral anticoagulants (DOACs) device market size is projected to experience significant growth in the coming years. It is expected to expand to $49.48 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is driven by factors such as technological progress in portable and point-of-care devices, the integration with digital health platforms and cloud-based monitoring, increasing adoption of personalized anticoagulation management, the expansion of homecare and specialty clinic services, and a rise in regulatory approvals for innovative monitoring systems. Prominent trends for the forecast period include the expanding use of point-of-care DOAC monitoring devices, a greater focus on factor Xa and direct thrombin inhibitor monitoring, growing awareness regarding stroke and thromboembolism prevention, the development of homecare and ambulatory monitoring solutions, and an enhanced emphasis on accuracy, sensitivity, and rapid testing capabilities.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp
What Primary Drivers Are Shaping The Development Of The Direct Oral Anticoagulants (DOACs) Device Market?
The rising occurrence of cardiovascular conditions is projected to boost the expansion of the direct oral anticoagulants (DOACs) device market in the future. These disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory issues. An increase in cardiovascular disorders is linked to increasingly sedentary lifestyles, which contribute to weight gain, higher blood pressure, and a gradual decline in cardiovascular function. Direct oral anticoagulants (DOACs) assist in managing cardiovascular disorders by effectively reducing the risk of stroke and blood clots in individuals with atrial fibrillation, providing dependable anticoagulation without requiring frequent blood tests. For example, in October 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, cardiovascular disease was responsible for 919,032 lives, representing one in every three deaths. Coronary heart disease continued to be the most common type of heart disease, and it was notable that approximately one in six deaths from cardiovascular diseases affected adults younger than 65 years. Consequently, the growing prevalence of cardiovascular disorders is propelling the growth of the direct oral anticoagulants (DOACs) device market.
Which Segment Classifications Shape The Direct Oral Anticoagulants (DOACs) Device Market?
The direct oral anticoagulants (doacs) device market covered in this report is segmented –
1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate
How Are Trends Impacting The Direct Oral Anticoagulants (DOACs) Device Market?
Leading firms within the direct oral anticoagulants (DOACs) device market are concentrating on creating sophisticated solutions, like automated coagulation assays, aiming to enhance the precision, effectiveness, and uniformity of direct oral anticoagulant level surveillance within clinical lab settings. These automated coagulation assays are machine-conducted laboratory examinations designed to assess the speed of blood clotting, assisting in the diagnosis of various bleeding or clotting conditions. As an illustration, in February 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, introduced three novel coagulation tests tailored for Factor Xa inhibitors. These tests improve clinicians’ capability to precisely assess the anticoagulation state of patients using direct Factor Xa inhibitors like rivaroxaban and apixaban. They support clinical decisions by accurately quantifying the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin during crucial situations such as bleeding events, overdoses, or emergency surgical procedures. Employing Roche’s reagent cassette technology on cobas t analyzers, these automated examinations provide superior results, reduce the need for manual intervention, and optimize the efficiency of laboratory workflows.
Which Companies Are Expanding Their Footprint In The Direct Oral Anticoagulants (DOACs) Device Market?
Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.
Read the full direct oral anticoagulants (doacs) device market report here:
How Does The Direct Oral Anticoagulants (DOACs) Device Market Perform Across Major Global Regions?
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Direct Oral Anticoagulants (DOACs) Device Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp
Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2026, By The Business Research Company
Machine Learning Market Report 2026
https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report
Financial Analytics Market Report 2026
https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report
Machine Learning Ml In The Pharmaceutical Industry Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model